The reason why our pps is so low is because MANF v
Post# of 30028
Posted On: 11/18/2014 2:44:44 PM
The reason why our pps is so low is because MANF value is so far into the future. Elto and ESS are a little closer. But it was the promise of Lympro revenue in 2015 and 2016 that gave some of us hope that the pps would rise to the levels Gerald has suggested we're worth. But with Gerald's vagary regarding LymPro revenue and Jason's horribly low estimates....it has taken the wind out of our sails. Without revenue in the near future, we will not be up listing for quite some time and our pps will remain where it is.
Why didn't the market react to today's good news? It truly was good news. Because it doesn't represent revenue in the near future. It is 2 to 4 years away at best. Gerald gave us a bone with the hope of international revenue for ESS earlier....but we have all choked over many of the bones Gerald has thrown out.
He needed to address jason's low Lympro revenue estimate, but he didn't. Big MBA business words that "talk" about value are nice, but at some point he has to deliver it instead of just talk about it.
Why didn't the market react to today's good news? It truly was good news. Because it doesn't represent revenue in the near future. It is 2 to 4 years away at best. Gerald gave us a bone with the hope of international revenue for ESS earlier....but we have all choked over many of the bones Gerald has thrown out.
He needed to address jason's low Lympro revenue estimate, but he didn't. Big MBA business words that "talk" about value are nice, but at some point he has to deliver it instead of just talk about it.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼